GLP-1s and Menopause: What the Evidence Shows in 2026

By Menopause Reviewed Editorial Team | Last reviewed: July 2026

Semaglutide and tirzepatide — GLP-1 and dual GIP/GLP-1 receptor agonists originally developed for type 2 diabetes and now dominant in obesity medicine — are being prescribed to women in perimenopause and postmenopause at rates unseen for any prior weight-loss drug. The reason is straightforward. Midlife women face a specific and biologically predictable shift in body composition: as estrogen declines, visceral adipose tissue accumulates, lean mass drops, and metabolic risk rises. A drug that can produce 15 to 20 percent weight loss in a demographic with historically poor response to lifestyle interventions is going to be prescribed heavily.

The question is not whether GLP-1s work in this group. They do. The question is what the trial data actually shows on the specific outcomes menopausal women should care about: weight loss magnitude by menopause stage, bone density, muscle mass, and whether these drugs affect menopause symptoms directly or only indirectly. Below is what the current evidence supports — and where honest gaps remain.

Why this question matters now

Menopause reshapes body composition independently of aging. A 2026 review in the Journal of Clinical Medicine analyzed cross-sectional and longitudinal cohort data and found that postmenopausal women show a consistent shift toward lower lean mass and greater central adiposity across all BMI categories. Visceral fat — the metabolically active depot around abdominal organs — rises even in women whose overall weight stays stable. This is driven by estrogen's role in fat distribution: estrogen normally promotes subcutaneous fat storage and blunts visceral fat expansion. When estrogen falls, the pattern reverses.

The clinical consequence is not cosmetic. Visceral adiposity is independently linked to cardiometabolic risk, insulin resistance, and cardiovascular events. Standard lifestyle interventions — diet and exercise — produce weight loss in menopausal women, but the effect is modest and the visceral fat compartment resists change more stubbornly than in younger populations. GLP-1s are attractive precisely because they target the compartment lifestyle interventions struggle with most.

Do GLP-1s work in postmenopausal women?

Yes, though slightly less than in premenopausal women. The most useful data come from a post hoc analysis of the STEP and OASIS 4 trial programs presented at Obesity Week 2025. Investigators stratified female participants (STEP 1, 3, 4, 5, 8, 9 pool: n=2,151; OASIS 4: n=151) by menopausal status — premenopausal, perimenopausal, and postmenopausal — and analyzed weight loss outcomes at 64 to 68 weeks.

Semaglutide 2.4 mg weekly (subcutaneous) and 25 mg daily (oral) both produced clinically meaningful weight loss across all three groups. Median reductions were slightly greater in premenopausal women and lowest in postmenopausal women, but even the postmenopausal group achieved reductions substantial enough to move the majority of participants from obesity to overweight or healthy-weight BMI categories. Waist circumference dropped by a median of 14 cm in postmenopausal women on subcutaneous semaglutide — a direct signal of visceral fat reduction.

The parallel evidence from the SELECT cardiovascular outcomes trial (Lincoff et al., New England Journal of Medicine, 2023) is arguably more important. In more than 17,000 participants with overweight or obesity and established cardiovascular disease, semaglutide 2.4 mg produced a 20 percent relative reduction in major adverse cardiovascular events versus placebo (HR 0.80; 95% CI 0.72–0.90). This was the first anti-obesity drug to demonstrate cardiovascular benefit on hard endpoints in a non-diabetic population. For menopausal women — whose cardiovascular risk climbs sharply after estrogen decline — that outcome carries weight independent of the number on the scale.

The bone density question

This is the outcome where the evidence deserves the most careful reading. Rapid weight loss from any cause is associated with bone density reduction, and postmenopausal women — already losing roughly 1 to 2 percent of hip bone mineral density (BMD) annually from estrogen decline — enter GLP-1 therapy with less reserve than most other groups.

The strongest human data come from a 2024 phase 2 RCT by Hansen and colleagues, published in eClinicalMedicine. Over 52 weeks, semaglutide reduced total hip areal BMD by an estimated treatment difference of -0.020 g/cm² (p = 0.001), corresponding to roughly a 2.6 percent loss. Lumbar spine BMD dropped by an ETD of -0.018 g/cm³ (p = 0.007) — approximately 2.1 percent. Bone resorption marker P-CTX rose significantly in the semaglutide group compared to placebo (p = 0.021), while bone formation marker P-PINP did not show a compensatory increase. In plain terms: bone was being broken down faster without being rebuilt at a matching rate.

A more recent 20-week exploratory pilot trial (Frontiers in Aging, 2025) in older adults on 1.0 mg weekly semaglutide found no statistically significant BMD change over that shorter horizon, but the group differences trended in the same direction as the Hansen data. A 2025 systematic review in Osteoporosis International concluded the current signal is a "modest reduction in BMD favoring resorption, similar to calorie restriction effects" — meaningful, but not necessarily catastrophic if managed proactively.

Not all evidence points the same way. Earlier studies in patients with type 2 diabetes (52-week RCTs of exenatide and dulaglutide) actually showed BMD stability or small gains. Large cardiovascular outcome trials including LEADER and SUSTAIN-6 have not identified increased fracture risk with liraglutide or semaglutide versus placebo, though these were not powered for skeletal endpoints. The mechanism appears to be dominated by rapid weight loss and reduced skeletal mechanical loading rather than a direct pharmacologic effect on bone.

What this means practically for menopausal women: a baseline DXA scan before starting therapy, and a follow-up at 12 to 24 months for anyone who loses more than 10 percent of body weight, is a reasonable approach. The Bone Health and Osteoporosis Foundation supports individualized assessment for high-risk populations. Resistance training and adequate calcium/vitamin D intake become non-negotiable adjuncts, not optional add-ons.

The muscle mass question

The other headline concern is skeletal muscle. A 2025 systematic review in Cureus summarized the tirzepatide body composition data: at doses producing roughly 21 percent mean weight loss, approximately 75 percent of the loss came from fat mass and 25 percent from lean mass. The proportion was consistent across age, sex, and degree of weight loss. Importantly, muscle fat infiltration — a marker of muscle quality — improved on tirzepatide, and reductions in fat-free muscle volume stayed within expected ranges based on UK Biobank reference data.

Twenty-five percent of total weight loss from lean mass is not unique to GLP-1s. It is roughly what diet, bariatric surgery, and most weight-loss interventions produce. The concern in menopause is that this loss stacks on top of the age- and estrogen-related sarcopenia that is already occurring. A postmenopausal woman losing 15 percent of body weight on semaglutide may lose 3 to 4 kg of lean mass — measurable but not disabling if paired with resistance training and adequate protein.

The evidence-based protective protocol is uncontroversial: 1.2 to 1.6 grams of protein per kilogram of body weight per day, resistance training two to three times weekly targeting major muscle groups, and monitoring grip strength or functional capacity as a practical proxy. Women who follow this protocol on GLP-1 therapy preserve substantially more lean mass than those who do not.

Do GLP-1s treat menopause symptoms?

This is a common question with a narrow answer. There is no direct evidence that GLP-1s reduce vasomotor symptoms — hot flashes and night sweats. They do not act on the KNDy neuron / neurokinin-3 receptor pathway that drives those symptoms. Anyone claiming otherwise is either extrapolating from weight-loss quality-of-life measures or making it up.

What GLP-1s do improve, according to a post hoc analysis of the STEP and OASIS programs by menopausal status, is quality of life across weight-related domains — including urinary incontinence, osteoarthritis pain, and physical function — with clinically meaningful improvements observed regardless of menopause stage. These are real effects and matter for women dealing with them. But they are downstream of weight loss, not treatments of menopause per se.

For vasomotor symptoms specifically, hormone therapy and fezolinetant remain the evidence-backed options. We cover the mechanism and treatment landscape in Hot Flashes Decoded.

Interaction with hormone therapy

One useful finding from the STEP subgroup analysis: in postmenopausal women, concomitant hormone therapy appeared to enhance semaglutide's weight-loss effect. Improvements in anthropometric measures were greater with HT than without. The sample size for this subgroup was modest and the finding is exploratory rather than confirmatory, but it aligns with the broader body of evidence showing that estrogen supports insulin sensitivity, fat oxidation, and preservation of lean mass — mechanisms that would plausibly amplify a GLP-1's effect.

The 2025 Expert Review of Endocrinology and Metabolism review "Implications of the era of incretin-based weight loss therapy in menopause" positioned semaglutide 2.4 mg as the anchor therapy for postmenopausal women with high cardiometabolic risk, citing both its 16.9 percent mean weight loss and its SELECT cardiovascular outcome. The authors called for GLP-1 use in eligible women (BMI ≥30, or ≥27 with comorbidities) to be treated as a cornerstone of cardiometabolic risk reduction, not a cosmetic weight-loss tool.

Practical protocol considerations

The evidence supports a specific set of practical decisions for menopausal women starting GLP-1 therapy:

• Baseline workup. A DXA scan for BMD (particularly for anyone over 60 or with prior fracture risk factors), fasting glucose, HbA1c, lipid panel, and thyroid function.
• Protein. 1.2–1.6 g/kg/day, distributed across meals. GLP-1s reduce appetite, so protein target may need to be met with intent rather than by feel.
• Resistance training. Two to three sessions weekly, focused on major muscle groups. Not optional if lean mass preservation is a goal.
• Calcium and vitamin D. 1,000–1,200 mg calcium and 800–1,000 IU vitamin D daily unless bloodwork suggests otherwise.
• Follow-up DXA. At 12–24 months, particularly if total weight loss exceeds 10 percent.
• Cardiovascular considerations. Blood pressure and lipid monitoring at 3, 6, and 12 months; semaglutide typically improves both.
• Gastrointestinal titration. Slow dose escalation reduces nausea substantially. Most trial data uses 16-week titration to full dose.

For women considering HT alongside GLP-1 therapy, current evidence suggests the combination is not only safe but potentially synergistic on body composition outcomes. Prescribing decisions should be individualized with a clinician familiar with both.

Bottom line

GLP-1s are the most effective pharmacologic intervention for weight loss and cardiometabolic risk reduction currently available to menopausal women with overweight or obesity. They work across menopause stages, they meaningfully reduce cardiovascular events on hard endpoints, and they improve weight-related quality of life. They also produce modest bone density loss, contribute to lean mass reduction proportional to weight loss, and do not directly treat menopause symptoms.

The clinical case for GLP-1 therapy in the right menopausal woman — elevated BMI, cardiometabolic risk factors, prior lifestyle intervention response poor — is strong. The case for treating them as a lifestyle drug divorced from a supportive protocol of resistance training, protein intake, and skeletal monitoring is not. Used well, they are among the most powerful tools available in midlife. Used casually, the musculoskeletal cost stacks unfavorably on top of an already declining baseline.

Menopause is not the reason to avoid GLP-1s. It is the reason to prescribe and use them more carefully.

References

1. Hurtado Andrade MD, et al. Semaglutide reduces body weight regardless of menopause status: STEP and OASIS 4 post hoc analysis. Obesity Week 2025 poster. Novo Nordisk ScienceHub
2. Andrade MD, et al. Impact of s.c. semaglutide 2.4 mg and oral semaglutide 25 mg on QoL in women with overweight or obesity: STEP and OASIS post hoc by menopausal status. Menopause Society 2025. Novo Nordisk ScienceHub
3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine. 2023;389:2221–2232. NEJM
4. Hansen M, Lund MT, Gregers E, et al. Effects of once-weekly subcutaneous semaglutide on bone mineral density: a phase 2 RCT. eClinicalMedicine. 2024. Summarized in clinical summary.
5. Zorrilla-Vaca A, Torres-Gutiérrez JL, et al. Effects of GLP-1 receptor agonists on bone health: a systematic review. Osteoporosis International. 2025. PMC
6. Bone mineral density and turnover response to GLP-1 receptor agonist therapy: 20-week pilot trial (NCT05786521). Frontiers in Aging. 2025. Frontiers
7. Systematic review: effects of tirzepatide on skeletal muscle mass in adults. Cureus. 2025. PMC
8. Effects of GLP-1 receptor agonists on bone mineral density in patients with T2DM: 52-week RCT. BioMed Research International. 2021. PMC
9. The impact of the menopausal transition on body composition. Journal of Clinical Medicine. 2026. PMC
10. Papadakis GE, Hans D, Rodriguez EG, et al. Menopausal Hormone Therapy Is Associated With Reduced Total and Visceral Adiposity: The OsteoLaus Cohort. Journal of Clinical Endocrinology and Metabolism. 2018. OUP Academic
11. Implications of the era of incretin-based weight loss therapy in menopause. Expert Review of Endocrinology and Metabolism. 2025. Taylor & Francis
12. The regulation of adipose tissue health by estrogens. Frontiers in Endocrinology. 2022. PMC